The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.
Vienna/Brno/Berlin – September 24, 2014: Colon cancer is one of the most common cancers being the second most common cause of cancer in women and the third most common in men. At the same time colon cancer is the fourth common cause of cancer related death. Early detection of this disease increases both the therapeutic success and the chance of survival. Current diagnostic practice involves either uncomfortable invasive procedures or uses stool tests, the latter resulting in a high percentage of false-positive results. The collaboration between BioVendor, SCIENION and AIT aims to use biomarkers for the early detection and screening based on patients blood samples. In the project, AIT’s proprietary biomarkers will be developed into an easy-to-use in-vitro diagnostic (IVD) test kit. The technology takes advantage of the fact that specific tumor autoantibodies can be detected in blood of cancer patients in a very early stage of tumor development.
Development of an in vitro test kit
The three companies will work closely together to develop the in-vitro diagnostic test for the global market. AIT provides their previously identified and patented biomarkers, specific for blood-based diagnosis of colon cancer. BioVendor, represented by its subsidiary company TestLine Clinical Diagnostics, will bring in its development expertise and distribution network. SCIENION contributes with its longstanding expertise in the microarray market and will be responsible for assay development and manufacturing using the company’s high-quality microtiter plates (sciPLEXPLATES).
Martin Weber, Head of the business unit Molecular Diagnostics at AIT, said: "We are entering the cooperation with BioVendor and Scienion extremely enthusiastic and we strongly believe that the newly formed consortium has the power to perfectly drive forward AITs breakthrough biomarker technologies into market-ready solutions."
"We share the excitement expressed by Martin. Early, cost-efficient and non-invasive diagnosis of colon cancer is a largely unmet medical need that presents the newly formed consortium with an attractive commercial opportunity", said Viktor Ružička, CEO of the BioVendor group.
Holger Eickhoff, CEO of SCIENION AG, commented: "We are very happy to expand our existing collaboration with BioVendor for this new project. Getting AIT with its proprietary biomarker panel on board as a third partner is the perfect match for the development of colon cancer IVD. Once established, our test kit has the potential for broad colon cancer screening applications."
About the AIT Austrian Institute of Technology
The AIT is Austria’s largest non-university research institute and is, among European research institutes, a specialist in key infrastructure issues. The Molecular Diagnostics business unit focusses on biomarkers, assay development, bioinformatics and diagnostic biosensors and has several patents on biomarkers for cancer. The group combines innovative high throughput technologies with their own in-house workflow-based data analysis tools to support partners and customers in the ultimate goal of defining biomarkers for personalized medicine and early disease detection.
About BioVendor
BioVendor is a developer and manufacturer of high-quality immunoassays, recombinant proteins, and antibodies. TestLine Clinical Diagnostics s.r.o. established in 1993, specializes in development, production and distribution of in vitro diagnostic kits for human and veterinary medicine. It is one of the most important producers and suppliers of diagnostic kits in the field of serology in the Czech Republic. Our products are routinely used throughout 40 countries around the world.
About SCIENION
SCIENION is a leading supplier of quality instrumentation and services for low volume liquid handling. Proprietary technologies include piezo electric dispensing, surface modifications and microarray manufacturing. Based on SCIENION’s core competencies in ultra-low volume liquid dispensing, assay miniaturization, and microarray manufacturing, the company provides an integrated product portfolio facilitating a number of applications: multiplex assays, DNA microarray production, biosensor loading, miniaturized PCR, peptide microarrays, protein microarrays, cell deposition.
Contact
Dr. Martin Weber
Donau-City-Straße 1
1220 Wien
Phone: 050550 4420
Fax: +: 050550 4450mailto:[email protected]http://www.ait.ac.at BioVendor Laboratorni medicina a.s.
Dr. Viktor Růžička
Karasek 1767/1
621 00 Brno
Czech Republic
Phone: +420-549 124 185
Fax: +420-549 211 460 mailto:[email protected]http://www.biovendor.com SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone: +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701 mailto:[email protected]http://www.scienion.com/